ImmuneRegen BioSciences, Inc. Appoints Investor Awareness, Inc. To Launch Investor Relations Program
SCOTTSDALE, Ariz., July 18 /PRNewswire-FirstCall/ -- ImmuneRegen BioSciences, Inc. , a wholly owned subsidiary of IR BioSciences Holdings, Inc., today announced it has retained the services of Investor Awareness, Inc. as its investor relations firm. Chicago-based Investor Awareness, Inc., a full service investor and media relations consulting firm, provides private and publicly traded companies with customized programs to generate awareness among members of the financial community. Investor Awareness specializes in accelerating the growth in the value of small to midsize companies.
Tony Schor, President of Investor Awareness, Inc., said, "We are pleased to work on behalf of ImmuneRegen BioSciences, Inc. during this exciting phase of their growth and development. With the Company's recent announcement of its agreement with the National Institutes of Health's (NIH) National Institute of Allergy and Infectious Diseases (NIAID) component to fund and conduct a preclinical anti-microbial evaluation of ImmuneRegen's proprietary compound Viprovex(TM) for potential use as a possible treatment for certain infectious respiratory diseases including influenza, measles and SARS, the timing is perfect to communicate the company's compelling story to the investment community."
"Investor Awareness, Inc. will play an integral role in ensuring we reach the investment community with our message," said Michael Wilhelm, President of ImmuneRegen BioSciences, Inc. "We believe that Investor Awareness, Inc. is uniquely qualified to represent us in view of our anticipated progress and growth. We have had the opportunity to work in the past with the Company and its management team and have continued to monitor its expansion of relationships and the advancement of their propriety research. It is with this in mind that we are confident the time is right for us to effectively generate awareness and convey the Company's strategy for continued growth."
About ImmuneRegen BioSciences, Inc.
IR BioSciences Holdings Inc., through its wholly owned subsidiary ImmuneRegen BioSciences, Inc., is a development stage biotechnology company focused on the research and development of Homspera(TM) and its derivatives Radilex(TM) and Viprovex(TM), which are designed to be used as countermeasures for multiple homeland security bioterrorism threats. Homspera is derived from modified Substance P, a naturally occurring peptide immunomodulator and homeostatic compound with the dual effect of improving pulmonary function and the stimulation of the human immune system. For more information, please visit the company's website at www.immuneregen.com.
Statements about the Company's future expectations, including statements about the potential for the Company's drug candidates, science and technology, and all other statements in this press release other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. The Company's actual results could differ materially from expected results as a result of a number of factors, including the fact that preliminary results involved only a small number of test mice, the uncertainties inherent in research and development collaborations, pre-clinical and clinical trials and product development programs, (including, but not limited to the fact that future results or research and development efforts may prove less encouraging than current results or cause side effects not observed in current pre-clinical trials) the evaluation of potential opportunities, the level of corporate expenditures, capital market conditions, and others set forth in the Company's periodic report on Form 10-Q for the three months ended March 31, 2006 as filed with the Securities and Exchange Commission. There are no guarantees that any of the Company's proposed products will prove to be commercially successful. The Company undertakes no duty to update forward-looking statements.
Investor relations: Tony Schor or Lindsay Kenoe Investor Awareness, Inc. 847-945-2222 www.investorawareness.com John N. Fermanis, CFO ImmuneRegen BioSciences, Inc. 480-922-3926 www.immuneregen.com MEDIA CONTACT: W. Jason Grimley Spelling Communications 310-477-9500 jgrimley@spellcom.com
ImmuneRegen BioSciences, Inc.CONTACT: Investor Relations, Tony Schor or Lindsay Kenoe, both of InvestorAwareness, Inc., +1-847-945-2222, for ImmuneRegen BioSciences, Inc.; orJohn N. Fermanis, CFO of ImmuneRegen BioSciences, Inc., +1-480-922-3926; orMedia, W. Jason Grimley of Spelling Communications, +1-310-477-9500,jgrimley@spellcom.com, for ImmuneRegen BioSciences, Inc.